Prolactin receptor messenger ribonucleic acid in normal and neoplastic human pituitary tissues

被引:29
作者
Jin, L
Qian, X
Kulig, E
Scheithauer, BW
CalleRodrigue, R
Abboud, C
Davis, DH
Kovacs, K
Lloyd, RV
机构
[1] MAYO CLIN & MAYO FDN, DEPT LAB MED & PATHOL, DIV ENDOCRINOL METAB & INTERNAL MED, ROCHESTER, MN 55905 USA
[2] MAYO CLIN & MAYO FDN, DEPT NEUROL SURG, ROCHESTER, MN 55905 USA
[3] ST MICHAELS HOSP, DEPT PATHOL, TORONTO, ON M5B 1W8, CANADA
关键词
D O I
10.1210/jc.82.3.963
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We examined the specific cell types in normal human pituitaries that expressed PRL receptor (PRL-R) messenger ribonucleic acid (mRNA) by combined in situ hybridization and immunohistochemistry. The distribution of PRL-R mRNA in 28 pituitary adenomas was examined by in situ hybridization and reverse transcription-PCR in 12 cases of adenomas. In another set of experiments, 34 PRL adenomas fi om men, women, and bromocriptine-treated patients were analyzed for PRL-R by in situ hybridization. In the normal pituitary, PRL- and LH-producing cells had significantly more mean grain counts per cell and higher percentages of cells positive for PRL-R than GH and TSH cells. PRL-R mRNA was present in all groups of adenomas by in situ hybridization and reverse transcription-PCR. PRL adenomas had a significantly higher density of labeling compared to other adenoma types. Although there was no difference in the levels of PRL-R mRNA in PRL adenomas from men and premenopausal and postmenopausal women, patients treated with bromocriptine before pituitary surgery had significantly lower levels of PRL-R compared to all other groups. These results indicate that in the normal pituitary, PRL and LH cells have the highest level of PRL-R mRNA, whereas PRL adenomas have significantly higher levels of PRL-R mRNA than other types of adenomas, and bromocriptine treatment decreases the levels of PRL-R mRNA in PRL adenomas.
引用
收藏
页码:963 / 968
页数:6
相关论文
共 37 条
[1]   SELECTIVITY OF JUXTAPOSITION BETWEEN CUP-SHAPED LACTOTROPHS AND GONADOTROPHS FROM RAT ANTERIOR-PITUITARY IN CULTURE [J].
ALLAERTS, W ;
MIGNON, A ;
DENEF, C .
CELL AND TISSUE RESEARCH, 1991, 263 (02) :217-225
[3]   DOPAMINE AGONISTS AND PITUITARY-TUMOR SHRINKAGE [J].
BEVAN, JS ;
WEBSTER, J ;
BURKE, CW ;
SCANLON, MF .
ENDOCRINE REVIEWS, 1992, 13 (02) :220-240
[4]   IDENTIFICATION OF A CDNA-ENCODING A LONG FORM OF PROLACTIN RECEPTOR IN HUMAN HEPATOMA AND BREAST-CANCER CELLS [J].
BOUTIN, JM ;
EDERY, M ;
SHIROTA, M ;
JOLICOEUR, C ;
LESUEUR, L ;
ALI, S ;
GOULD, D ;
DJIANE, J ;
KELLY, PA .
MOLECULAR ENDOCRINOLOGY, 1989, 3 (09) :1455-1461
[5]   PROLACTIN RECEPTORS IN HUMAN PITUITARY-ADENOMAS [J].
CICCARELLI, E ;
FACCANI, G ;
LONGO, A ;
ORE, GD ;
PAPOTTI, M ;
GROTTOLI, S ;
RAZZORE, P ;
GHE, C ;
MUCCIOLI, G .
CLINICAL ENDOCRINOLOGY, 1995, 42 (05) :487-491
[6]  
CICCARELLI E, 1996, INT PIT C
[7]  
CLEVENGER CV, 1995, AM J PATHOL, V146, P695
[8]   AUTORADIOGRAPHIC LOCALIZATION OF BINDING OF I125 LABELED PROLACTIN TO RAT TISSUES INVITRO [J].
COSTLOW, ME ;
MCGUIRE, WL .
JOURNAL OF ENDOCRINOLOGY, 1977, 75 (02) :221-&
[9]   COMPARATIVE LOCALIZATION OF PROLACTIN-BINDING SITES IN DIFFERENT RAT-TISSUES BY IMMUNOHISTOCHEMISTRY, AUTORADIOGRAPHY AND RADIORECEPTOR ASSAY [J].
DUBE, D ;
KELLY, PA ;
PELLETIER, G .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1980, 18 (02) :109-122
[10]  
DUTT A, 1994, NEUROENDOCRINOLOGY, V59, P413, DOI 10.1159/000126686